Johnson & Johnson (JNJ)
265.58
-0.77
(-0.29%)
USD |
NYSE |
Sep 11, 16:00
266.05
+0.47
(+0.18%)
After-Hours: 20:00
Johnson & Johnson Enterprise Value : 667.86B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 667.86B |
| September 10, 2026 | 669.71B |
| September 09, 2026 | 671.47B |
| September 08, 2026 | 676.38B |
| September 04, 2026 | 691.09B |
| September 03, 2026 | 698.80B |
| September 02, 2026 | 691.05B |
| September 01, 2026 | 681.37B |
| August 31, 2026 | 668.51B |
| August 28, 2026 | 673.78B |
| August 27, 2026 | 668.31B |
| August 26, 2026 | 678.50B |
| August 25, 2026 | 686.06B |
| August 24, 2026 | 685.82B |
| August 21, 2026 | 679.08B |
| August 20, 2026 | 672.17B |
| August 19, 2026 | 686.71B |
| August 18, 2026 | 681.17B |
| August 17, 2026 | 660.12B |
| August 14, 2026 | 655.26B |
| August 13, 2026 | 659.43B |
| August 12, 2026 | 656.49B |
| August 11, 2026 | 653.94B |
| August 10, 2026 | 658.78B |
| August 07, 2026 | 652.59B |
| Date | Value |
|---|---|
| August 06, 2026 | 647.14B |
| August 05, 2026 | 648.61B |
| August 04, 2026 | 642.21B |
| August 03, 2026 | 640.96B |
| July 31, 2026 | 645.63B |
| July 30, 2026 | 644.35B |
| July 29, 2026 | 667.73B |
| July 28, 2026 | 670.62B |
| July 27, 2026 | 668.75B |
| July 24, 2026 | 662.61B |
| July 23, 2026 | 652.66B |
| July 22, 2026 | 643.89B |
| July 21, 2026 | 631.80B |
| July 20, 2026 | 627.49B |
| July 17, 2026 | 637.66B |
| July 16, 2026 | 630.26B |
| July 15, 2026 | 623.16B |
| July 14, 2026 | 639.61B |
| July 13, 2026 | 649.05B |
| July 10, 2026 | 647.14B |
| July 09, 2026 | 652.25B |
| July 08, 2026 | 662.61B |
| July 07, 2026 | 671.85B |
| July 06, 2026 | 652.80B |
| July 02, 2026 | 661.74B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.096T |
| Merck & Co., Inc. | 402.09B |
| Pfizer Inc. | 209.77B |
| Bristol Myers Squibb Co. | 164.00B |
| Liquidia Corp. | 5.845B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 5.534B |
| Revenue (Quarterly) | 25.32B |
| Total Expenses (Quarterly) | 19.78B |
| EPS Diluted (Quarterly) | 2.268 |
| Gross Profit Margin (Quarterly) | 68.73% |
| Profit Margin (Quarterly) | 21.86% |
| Earnings Yield | 3.25% |
| Operating Earnings Yield | 4.08% |
| Normalized Earnings Yield | 3.569 |